8th May - Trading Halt Convo Thread, page-51

The performance share is based on the company to achieve $20mil revenue by the end of this financial year. (if I remember correctly.) I believe this WHO is the only chance that management can achieve the revenue by then considering the delay of the American trials. The way I see it, if it is a good news, then everyone will be happy including us. If it is bad, well, there will be millions less shares issued, so probably not that bad either.

However, last week's new deal with UQ does get me a little bit concerned. It sounds like that the trials with WHO was not that great as there are background noise. Maybe, this ann is about extending the trials a little longer?